SEC Form 4 · accession 0001209191-17-021128
IRONWOOD PHARMACEUTICALS INC · IRWD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark G Currie
Officer — Chief Scientific Officer
Period of report
Mar 14, 2017
Accepted (ET)
Mar 16, 2017 · 5:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001446847
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class B Common Stock | Mar 14, 2017 | M | 60,000 | $3.76 | A | 835,000 | D | |
| Class B Common StockF1 | Mar 14, 2017 | S | 60,000 | $17.06 | D | 775,000 | D | |
| Class A Common Stock | holding | — | — | — | 21,258 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $3.76 | Mar 14, 2017 | M | 60,000 | D | — | Jan 31, 2018 | Class B Common Stock | 60,000 | 60,000 | D |
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.99 to $17.15, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- F2The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2008 for the first 36 months, and 4.5833% of the shares of Class B Common Stock vested on each monthly anniversary thereafter for the next 12 months. This option was fully vested as of January 1, 2012.